title: Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.
abstract: The kinetics of serum HBsAg and interferon-inducible protein 10 (IP10) levels in patients with chronic hepatitis B infection treated with tenofovir are unclear. We evaluated the changes of HBsAg levels and the predictability of IP10 for HBsAg decline in 160 HBeAg-negative patients receiving tenofovir for ≥12 months. Serum samples taken before and at 6, 12, 24, 36 and 48 months after tenofovir were tested for HBsAg levels. In 104 patients, serum samples before tenofovir were tested for IP10 levels. Compared to before tenofovir, HBsAg levels decreased by a median of 0.08, 0.11, 0.24, 0.33 and 0.38 log10 IU/mL at 6, 12, 24, 36 and 48 months, respectively (P < 0.001). HBsAg kinetics did not differ between nucleos(t)ide analogue(s) naive and experienced patients. The 12-, 24-, 36- and 48-month cumulative rates of ≥0.5 log10 HBsAg decline were 8%, 16%, 24% and 41% and of HBsAg ≤100 IU/mL were 9%, 12%, 14% and 18%, respectively. The only factor associated with HBsAg ≤100 IU/mL was lower HBsAg levels before tenofovir (P < 0.001), while HBsAg decline ≥0.5 log10 was associated with higher IP10 levels (P = 0.002) and particularly with IP10 > 350 pg/mL (P < 0.001). In conclusion, tenofovir decreases serum HBsAg levels in both nucleos(t)ide analogue(s) naive and experienced patients with HBeAg-negative chronic hepatitis B infection. After 4 years of therapy, HBsAg ≤100 IU/mL can be achieved in approximately 20% of patients, particularly in those with low baseline HBsAg levels. HBsAg decline is slow (≥0.5 log10 in 40% of patients after 4 years) and is associated only with higher baseline serum IP10 levels.
authors.affiliation: Department of Gastroenterology, Athens University Medical School, Laiko Hospital of Athens, Athens, Greece.
authors.forename: G
authors.initials: G
authors.lastname: Papatheodoridis
authors.affiliation: Department of Gastroenterology, University Hospital of Patras, Patras, Greece.
authors.forename: C
authors.initials: C
authors.lastname: Triantos
authors.affiliation: 2nd Department of Internal Medicine, Athens University Medical School, Hippokratio Hospital of Athens, Athens, Greece.
authors.forename: E
authors.initials: E
authors.lastname: Hadziyannis
authors.affiliation: Department of Gastroenterology, University Hospital of Patras, Patras, Greece.
authors.forename: K
authors.initials: K
authors.lastname: Zisimopoulos
authors.affiliation: Department of Gastroenterology, Athens University Medical School, Laiko Hospital of Athens, Athens, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Georgiou
authors.affiliation: Department of Gastroenterology, Athens University Medical School, Laiko Hospital of Athens, Athens, Greece.
authors.forename: T
authors.initials: T
authors.lastname: Voulgaris
authors.affiliation: Department of Gastroenterology, Athens University Medical School, Laiko Hospital of Athens, Athens, Greece.
authors.forename: I
authors.initials: I
authors.lastname: Vlachogiannakos
authors.affiliation: Department of Gastroenterology, University Hospital of Patras, Patras, Greece.
authors.forename: V
authors.initials: V
authors.lastname: Nikolopoulou
authors.affiliation: 2nd Department of Internal Medicine, Athens University Medical School, Hippokratio Hospital of Athens, Athens, Greece.
authors.forename: S
authors.initials: S
authors.lastname: Manolakopoulos
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D054357:Chemokine CXCL10 / Q000097:blood*; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000097:blood* / Q000276:immunology; D006513:Hepatitis B e Antigens / Q000097:blood* / Q000276:immunology; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068698:Tenofovir / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D054357:Chemokine CXCL10; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D000068698:Tenofovir
keywords: HBsAg; hepatitis B; interferon-inducible protein 10; tenofovir